Compare Mesoblast Limited (MESO) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Schwab US Large Cap Growth ETF — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Schwab US Large Cap Growth ETF trades at $35.63. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SCHG | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $35.83 |
52-Week Low | $12.88 | $28.10 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
SCHG trades at $35.61, down 0.61% today, with a bullish technical trend supported by moving averages but neutral oscillators. The ETF focuses on U.S. large-cap growth stocks, benefiting from AI and technology themes, though key financial ratios are not disclosed in the provided data. Recent news highlights its low 0.04% expense ratio and strong historical performance, with institutional activity showing mixed positions.
Outlook remains positive due to exposure to growth sectors like AI, but risks include high concentration in top holdings and sensitivity to interest rates. Analyst sentiment is generally favorable, emphasizing long-term growth potential despite valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
